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Abstract: In the absence of a cure, the primary goals in managing Parkinson’s disease (PD) are to 
preserve functionality and health-related quality of life (HRQoL). Current therapeutic   strategies 
for PD include symptomatic treatment and are primarily focused on replacing dopamine in the 
brain. Dopamine agonists can be used as an alternative initial levodopa therapy, to delay the 
onset of motor complications, but at the expense of more dopaminergic adverse effects; poorer 
control of motor symptoms; and increased cost. In PD, treatment effects and costs accumulate 
over time; hence the choice of time horizon in cost-effectiveness analysis can be particularly 
important. Pharmaceutical expenditures have grown rapidly in recent decades and now total 
nearly 10% of all health care costs. The main approach to treat PD at the present time is to 
advance knowledge of the efficacy, to reduce long-term complications associated with treatment, 
and to improve patient HRQoL and society burden. The implementation of cost-effectiveness 
studies, including the societal perspective, should be considered as an outcome of new therapy 
strategies, which would be helpful to health care decision makers.
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Introduction
Parkinson’s disease (PD) is an age-related illness, primarily affecting the elderly 
population and often resulting in a marked decline in the health-related quality of 
life (HRQoL) of both patients and caregivers.1,2 Data from several studies show that 
PD represents a serious health problem, resulting in increased health expenditures 
and loss of productivity.3 In view of current demographic trends; the progressive and 
  long-term nature of PD; and the proportion of people with the disease, the ensuing use 
of health care resources will increase.4–8 Current therapeutic strategies for PD include 
symptomatic treatment which is primarily focused on replacing dopamine in the brain. 
As levodopa has provided the greatest symptomatic benefit with the fewest short-term 
adverse effects, it is still considered the gold standard of symptomatic treatment. 
However, long-term levodopa is associated with fluctuations in motor performance, 
dyskinesias, and neuropsychiatric complications.9,10 Dopamine agonists can be used 
as an alternative initial therapy, to delay the onset of motor complications, but at the 
expense of more dopaminergic adverse effects; poorer control of motor symptoms; 
and increased cost.11 Thus, the main approach to treat PD at the present time is to 
advance knowledge of the efficacy, to reduce long-term complications associated with 
treatment and to improve patient HRQoL and society burden.
Cost effectiveness studies of PD therapeutic interventions are therefore essential 
to help the decision making of care providers, affected individuals and their   families, ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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and policy makers, and also for predicting alternative 
  interventions. Therefore, the main purpose of this review 
was to evaluate the current knowledge of cost-effectiveness 
and patient acceptability of pharmacotherapy and other 
interventions in early PD.
Effectiveness outcomes
Clinical effectiveness outcomes
In order to evaluate the clinical effectiveness of PD interven-
tions, most clinical trials use surrogate endpoints or focus 
on PD symptoms severity, complications, or impact on 
patient HRQoL. However, assessing clinical effectiveness 
outcomes is highly complex due to the wide spectrum of 
PD symptoms, complications, and lifelong progression of 
the disease. In this regard, several different rating scales 
have been developed to assess various effectiveness out-
comes in PD patients. The first simple descriptive staging 
scale for PD was that of Hoehn and Yahr (HY),12 designed 
to provide a general estimate of clinical function in PD, 
based on the concept that the severity of PD was related to 
  bilateral motor dysfunction and impairment of gait and bal-
ance (ranging from Stage I, with unilateral presence of motor 
symptoms; to Stage V, being wheelchair- or bed-bound). 
However, because the broad categories of the HY scale do 
not allow consistent identification of effective interventions,13 
the scale that has been largely used in clinical trials is the 
  Unified Parkinson’s Disease Rating Scale (UPDRS),14 and 
its new version, the Movement Disorder Society-sponsored 
revision of the   Unified Parkinson’s Disease Rating Scale 
(  MDS-UPDRS),15 designed to accommodate new advances 
and to resolve problematic areas. The MDS-UPDRS has four 
parts: I – Non-motor Experiences of Daily Living; II – Motor 
Experiences of Daily Living; III – Motor Examination; 
  IV – Motor   Complications. Twenty questions are completed 
by the patient/caregiver. The published data supports the 
validity of this scale for rating PD.
As important as economic costs are to any discussion of 
PD-related resource utilization, it is also critical that payers 
and providers consider the significant impact the disease has 
on HRQoL, which assesses an individual’s perceived effect 
of the illness on their physical, psychological, and social 
daily lives. It is important for determining the   effectiveness 
of therapies for PD at both individual and population 
  levels. For care provider managers, it presents an important 
  parameter to measure the effectiveness of management 
strategies and   quality of care. HRQoL measures are also 
important in assessing the value of drug therapy, particularly 
for chronic conditions such as PD, and in determining the 
appropriate placement of medications on plan formularies. 
As would be expected for any chronic and progressively 
worsening disorder, PD has a significant impact on the 
HRQoL of both patients and their caregivers. Of note, 
non-motor disability (particularly depression, insomnia, 
and other mental health factors) appears to have a greater 
negative effect on HRQoL than motor deficits.16,17 The most 
common generic health   profile measures to evaluate PD are 
the Nottingham Health Profile (NPH),18,19 the 36-Item Short 
Form General Health Survey (SF36),20 and the Sickness 
Impact Profile (SIP).21   Utility measures used include the 
EQ-5D™ and the Health Utility Index.22,23 However, most 
of the cost-effectiveness analyses have used the EQ-5D22 
as a measurement of HRQoL, or quality-adjusted life years 
(QALYs). The EQ-5D consists of five questions (mobility, 
self care, usual activities, pain, and anxiety/depression) 
and an additional visual analog scale on which patients rate 
their current health status. QALYs, or years of healthy life, 
are used instead in order to quantify time and health. The 
QALY concept comprises two qualities: the first, the time 
component that considers the gain or loss of life time due to 
the choice of a certain treatment strategy; and the second, the 
HRQoL is measured by its value on a scale from 0 (death) 
to 1 (perfect health).13 Thus, one QALY means a period of 
1 year under the condition of perfect health. On the other 
hand, disease-specific instruments are usually more respon-
sive to a change in health status of a particular patient group 
compared with generic instruments.24 HRQoL-specific mea-
sures of PD include the PDQ-39,25 the Parkinson’s disease 
quality of life questionnaire (PDQL),26,27 and the Parkinson’s 
Impact Scale (PIMS).28
Cost-effectiveness of treatment options
In cost-of-illness studies, three types of costs are evaluated, 
including direct; indirect; and intangible costs. Direct costs 
arise directly from the treatment of the disease, while   indirect 
costs refer to indirect consequences of the disease, such 
as loss of work and early retirement. Intangible costs are 
costs that cannot be directly expressed in monetary   values, 
such as happiness or anxiety due to a disease. Another 
  controversially discussed cost component to consider in 
cost analysis studies is informal care (care by volunteers 
such as family members or friends), because from the 
perspective of a third-party payer, the costs of informal 
care are   irrelevant (as are indirect costs). They cannot be 
reimbursed, but   considered from a societal perspective, they 
should be   legitimately included.13 McCrone et al, using a 
regression analysis, identified significant baseline   predictors ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
129
Pharmacotherapy in early Parkinson’s disease
of follow-up costs in PD.29   According to these authors, 
formal service costs accounted for 20% of this figure, with 
informal care from families/friends   accounting for 80%. 
The regression model explained 42% of total follow-up 
costs, and significant predictors included gender (with men 
  having higher costs), disability, and depression. However, 
the majority of authors conclude that in PD, along with costs 
for hospitalization, drug costs are consistently the main cost 
driver of direct costs.13,30,31 Direct and indirect costs related 
to PD increase with the progression of the disease. Over 
time, the direct costs of patients with predominant akinetic-
rigid PD phenotype are higher than those with predominant 
tremor, and unaffected peers.32
There are different types of economic evaluations, but 
cost-effectiveness analysis and cost-utility analysis are 
usually the preferred analyses that help decision   makers 
in the allocation of restricted health care resources.13 
  Cost-  effectiveness analysis measures the benefit of a health 
intervention in   relation to costs, and represents the cost of 
the treatment option in monetary units by the expected 
  effectiveness measures in natural units, such as, for example, 
UPDRS score decrease.33,34 However the main critique of this 
type of evaluation is the difficulty of comparing between 
  different patient populations with different diseases.13 
Instead, to compare interventions for different diseases, one 
has to use a generic denominator such a QALYs, which 
can be calculated on the basis of the patient’s subjectively 
assessed HRQoL, and are based on patient preferences. This 
is called   cost-utility analysis. The latter gives us the additional 
amount of money one has to pay for therapeutic interventions 
to gain one more QALY.13
For health maker decisions, two approaches have freq-
uently been used: decision trees and Markov models. In deci-
sion trees, one decision node and its roots and all branches 
of the initial decision node are represented as   treatment 
options that are to be compared. This type of approach is 
useful if the outcomes to analyze are short-term, the duration 
of the disease is short, and if events within the course of a 
disease do not occur repeatedly.13 Markov models, on the 
other hand, allow for the synthesis of data on cost, effects, 
and HRQoL of alternative clinical strategies, by assigning 
values to a series of health states over time.
Cost-effectiveness in early PD
Over the last years, a growing number of randomized con-
trolled trials of medical therapies have included economic 
evaluations and HRQoL as secondary outcomes. These kinds 
of evaluations can provide data about the value of a drug or 
technique when it is introduced into the market. A search of 
the published literature from January 1st 1990 to February 
15th 2010 was undertaken using the keywords:   “Parkinson”; 
“Parkinson’s disease”; “cost”; “cost   effectiveness”; and 
“  quality of life”, in combination. Databases searched were 
PubMed and the Cochrane Library. Only English   language 
publications which included patients with early PD, defined 
as having disease duration less than two years, were 
considered.
Cost-effectiveness of new techniques  
to diagnose PD
Diagnostic errors occur in 10%–25% of PD patients managed 
by general neurologists, leading to delayed or   inappropriate 
therapy initiation.35,36 New imaging techniques use radioac-
tive tracers, such as 123I-ioflupane (123I-FP-CIT), to provide 
earlier and more accurate diagnosis than that of the standard 
clinical assessment.37 The 123I-FP-CIT tracer binds to the 
striatal dopamine transporter (DAT) and is used in combi-
nation with single photon emission computed tomography 
(SPECT) to identify dopaminergic deficits.36 The economic 
advantages associated with the use of 123I-FP-CIT SPECT 
(DaTSCAN) may vary depending on the prevalence of PD 
in the group of patients with uncertain diagnosis; the cost of 
routine clinical evaluation including other diagnostic tests; 
and the consequences of either delaying or inappropriately 
instituting dopaminergic therapy.38 In one recent study by 
Antonini et al, conducted from an Italian National Health 
System perspective, DaTSCAN was compared to clinical 
judgment alone for differentiating essential tremor from PD.37 
Based on the Markev models, over 5 years, the estimated 
cost-effectiveness of DaTSCAN was under 1000 Euros (�) 
per potentially beneficial therapy (2005 values) gained when 
the underlying disease prevalence is high (55%–70%), and 
cost-saving at a prevalence under 55%. These authors con-
cluded that DaTSCAN is likely to be economically advanta-
geous to differentiate essential tremor from PD, increasing 
time on potentially beneficial therapy, at lower overall cost 
to the health care system.37 However further studies are 
required to validate these results in different national health 
care systems.
Cost-effectiveness of dopaminergic drugs
Pharmacological treatments have been directed   primarily at 
dopamine replacement with levodopa and agents to improve 
its bioavailability. These include DOPA   decarboxylase 
inhibitors; catechol-O-methyltransferase (COMT)   inhibitors; 
and monoamine oxidase B (MAO-B) inhibitors, as well as ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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synthetic dopamine agonists. There is still uncertainty as to 
when to start medical treatment in PD. The issue of whether 
to adopt a “wait and watch” strategy or to initiate drug 
therapy soon after diagnosis in PD has been the subject of 
some debate. A recent observational study supported early 
  treatment by demonstrating deterioration in self-reported 
health status in those left untreated, but not those who 
received therapy.39 There is therefore increasing evidence of 
a negative influence on disease progression by delayed onset 
of medical drug treatment in PD. However, on the other hand, 
it seems that drug treatment in early PD patients increases 
health values, but the incremental cost-  effectiveness ratio is 
high.40 Greater awareness of a   prodromal/pre-motor stage 
of the disease; efforts toward early and accurate diagnosis; 
and the continuous   refinement of treatment paradigms, 
  provide an opportunity for   discussion on the use of potential 
  disease-modifying agents to slow or halt the progression of 
motor and non-motor disability. Such compounds could not 
only significantly improve patient and caregiver quality of 
life, but substantially reduce direct and indirect costs.
To date, numerous compounds have been evaluated in 
clinical trials, including coenzyme Q10; creatine; levodopa; 
pramipexole; rasagiline; ropinirole; and selegiline. None have 
demonstrated irrefutable and enduring disease-modifying 
qualities, although the best available clinical evidence 
appears most promising for rasagiline. Another important 
issue to be considered is that, although effective treatment 
of motor symptoms of PD is a central consideration to 
facilitate improved outcomes, management of non-motor 
symptoms is an equally, still to be improved, important 
target of intervention, since these symptoms can contribute 
greatly to disability.
We studied the impact of motor and non-motor   symptoms 
on PD direct costs based on the Spanish National Health 
  System (2004 � values).31 Average three month total direct cost 
of PD was 2,631 ± 4,507 � per person (range: 71,5–29,159) 
and medical treatment was the main cost driver, accounting 
for 34% of the cost (mean drug cost per person: 669 ± 406 �). 
PD direct costs were significantly higher among younger 
patients, with higher disease severity, motor impairment, 
complications and had a higher impact on the direct costs of 
PD than non-motor symptoms. This finding can be at least 
partially explained due to the lack of effective treatment for 
the majority of non-motor symptoms.
As dopaminergic drugs can also be used for PD and 
restless legs syndrome, the review of cost-analysis of dopa-
minergic drugs included in this article applied to PD only. 
In this review, because ergot agonists are no longer in use, 
and in agreement with the published literature, only first-line 
treatment for early PD was included (selegiline, rasagiline, 
pramipexole, and ropinirole). No cost-effectiveness studies 
for rotigotine were identified at the present time.
Selegiline
Selegiline, the first selective inhibitor of monoamine oxidase 
type B inhibitor (MAO-B), described in the literature, is a 
selective, irreversible cerebral that is used in the treatment 
of PD. It has a relatively mild adverse effect profile, with no risk 
of the tyramine (‘cheese’) reaction at normal therapeutic doses. 
Selective MAO-B inhibitors, used as monotherapy, delay the 
need for the introduction of levodopa by about nine months, 
although the relative contribution of neuroprotective and 
symptomatic effects of selegiline in these patients has yet to 
be clarified. These agents appear to be less efficacious than 
dopamine agonists, but are better   tolerated. Concern has 
been expressed about the potential of the MAO-B inhibitor 
selegiline to induce cardiovascular adverse effects (orthostatic 
hypotension), either directly or through its amphetamine 
catabolites.41 From a societal perspective, an old study 
  concluded that the economic benefits of selegiline therapy are 
likely to be substantial.42 An agent which slowed progression 
of disability by around 10% would realize   savings, through 
reduction in both direct and indirect costs, in the order of 
330 million US dollars (USD) per annum in the United States 
(1992 USD values).42 No other studies could be identified 
comparing selegiline with dopaminergic agonists, which 
are the preferred treatment option of patients with early PD 
without comorbidities, or with the other MAO-B inhibitor, 
rasagiline.
Rasagiline
Rasagiline is a second-generation MAO-B inhibitor that 
  selectively and irreversibly inhibits brain MAO-B,   specifically 
designed for the treatment of PD. In one recent study, the cost 
effectiveness, from a United Kingdom health care payer 
perspective, of two anti-Parkinsonian treatment strategies 
in early PD (first-line monotherapy with rasagiline; and 
the   non-ergoline dopamine receptor agonist pramipexole) 
was   analyzed over a 5-year period, using an economic 
Markov model.45 Utility and costs of these two strategies 
and   effectiveness outcomes were: i) time to levodopa; and 
ii) time to levodopa-induced dyskinesia. These authors found 
that, compared with pramipexole, the use of the rasagiline 
strategy was estimated to reduce costs by 18% per patient 
over 5 years and was associated with an additional 10% 
delay in dyskinesia onset (0.41 years; 95% CI: 0.27–0.55). ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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This   strategy was also found to prolong the time to levodopa 
  initiation by 25%, through a gain of 0.83 levodopa-free years 
(95% CI: 0.56–1.1). In addition, use of the rasagiline strategy 
was found to generate a 5% gain in QALYs over 5 years, 
compared with the pramipexole   strategy (3.7 ± 0.02 vs 
3.51 ± 0.03).43 In addition, rasagiline seemed to improve 
HRQoL compared with   placebo.44 This HRQoL improvement 
appears to be accounted for primarily by the symptomatic 
benefit of   rasagiline. Interestingly, by using the PDQL ques-
tionnaire, most of this benefit was found in the self-image/
sexuality domain. However, further cost-effectiveness   studies 
comparing rasagiline with other dopaminergic agonists are 
required.
Pramipexole
Evidence from pre-clinical studies and clinical trials has 
proven the effectiveness of pramipexole in ameliorating 
the symptoms of PD. There is also evidence in animal 
  studies that this agent, a nonergoline dopaminergic   agonist, 
may be neuroprotective and could therefore possibly slow 
disease   progression; however, this has yet to be proven 
in humans. The use of pramipexole may be limited by its 
side effects   profile compared to standard therapies and its 
relatively higher cost compared to levodopa.45 Different 
studies have been published looking at the cost-effectiveness 
of   pramipexole with no levodopa therapy, compared to 
levodopa   monotherapy and to rasagiline in early PD.43,46–49 
Hoerger et al46 used mathematical equations to link UPDRS 
parts (II and III scores), to analyze costs and QALYs 
in a US setting. For patients with early PD, treatment 
with   pramipexole had higher costs, but was more effec-
tive than baseline   treatment. For patients with early onset 
of PD, the incremental total cost-effectiveness ratio for 
pramipexole was 8,837 US dollars (USD)/QALY and direct 
costs were USD 67,702 for pramipexole   compared to USD 
57,549 for the baseline treatment. On the other hand, costs 
of loss of productivity were USD 97,391 for pramipexole 
versus USD 104,937 for baseline treatment (1997   costings). 
The authors concluded that it indicated higher costs for 
patients with early PD in the US receiving pramipexole, 
than for those not taking the drug, but additional quality 
life-years were gained.
In one longitudinal study, the two-year incremental cost 
effectiveness of initial pramipexole treatment was compared 
with initial levodopa treatment in 301 subjects with early 
PD, randomized to either agent.47 Pramipexole strategy 
was an estimated USD 2,138 ± 1,182 more expensive than 
levodopa strategy. The incremental cost-effectiveness of 
pramipexole compared with levodopa was USD 106,900/
QALY (EQ-5D), compared with pramipexole being 
dominated by levodopa using the EQVAS (2002   costings). 
After four years of follow-up, the cost-effectiveness of 
pramipexole compared with levodopa in the treatment 
of early PD increased as the time horizon of the clinical 
trial extended from two to four years.48 Using the cost-
  effectiveness acceptability curves to estimate the probability 
that pramipexole was cost-effective, given   different societal 
values of QALY, the probability that pramipexole was 
cost-effective relative to levodopa over the first four years 
was 0.57, 0.77 and 0.82, when a QALY was valued at USD 
50,000, USD 100,000, and USD 150,000 respectively (2002 
USD costs). Over time, the   incremental cost-effectiveness 
ratio for pramipexole improved and uncertainty around the 
incremental   cost-effectiveness ratio decreased. Likewise, 
HRQoL improved in   pramipexole   subjects and declined in 
levodopa subjects, and the   probability of pramipexole being 
cost-effective increased to 0.88, 0.96, and 0.98 respectively. 
The authors also found that   pramipexole seemed to be more 
cost-effective for patients with depression and low baseline 
HRQoL. However, it seems that the methodology applied to 
evaluate cost-effectiveness had an impact on the result. One 
study by Noyes et al49 found that country-specific preference 
weights in clinical-economic trials might have important 
effects on estimates of   incremental cost-effectiveness. Using 
US preference weights rather than UK preference weights 
reduced the probability that pramipexole was cost-effective 
compared to levodopa.
Ropinirole
Ropinirole is a non-ergoline dopamine agonist that binds to 
dopamine D2-receptors; the drug is indicated for use in the 
symptomatic treatment of early and late PD. In one cost-
  minimization study, conducted to examine the economic 
impact of reducing dyskinesias using ropinirole instead 
of levodopa plus benserazide in PD,50 the authors found, 
from the perspective of the Canadian Ministry of Health, 
that ropinirole was more expensive than levodopa. The 
analysis yielded an incremental expected daily cost/patient 
of 4.41 Canadian   dollars (CAD) for substituting levodopa 
plus benserazide with ropinirole. On the other hand, from a 
  societal perspective, in which loss of productivity was the 
major factor, ropinirole was cost-saving, after   off-setting 
the drug costs. The added costs of ropinirole were counter-
  balanced by savings due to reduced dyskinesias and associ-
ated downstream costs were also examined (1999 CAD). 
The main criticism of this study was that important cost and ClinicoEconomics and Outcomes Research 2010:2 submit your manuscript | www.dovepress.com
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resource-utilization data were estimated by experts, which 
can limit extrapolation.13
Cost-effectiveness of nonpharmacological 
treatments
Despite optimal medical management, most PD patients 
become progressively disabled. Allied health care usually 
provide complementary benefits to PD patients, even for 
symptoms that are resistant to pharmacotherapy or surgery.51 
Clinical experience suggests that optimal management 
requires a multidisciplinary approach, with multifactorial 
health plans tailored to the needs of each individual patient. 
However, little is known about the cost-effectiveness of a 
  multidisciplinary team approach. Since the first   guideline on 
physical therapy published in 2004,52 providing recommen-
dations for   evidence-based interventions, the quantity and 
quality of clinical trials evaluating the efficacy of   physical 
therapy in PD have evolved rapidly. In one interesting study 
by   Munneke et al, the efficacy of physical therapy provided 
by expert physiotherapists (ParkinsonNet networks) was 
compared to usual care.53 Whereas implementation of 
  ParkinsonNet networks did not change health outcomes, 
health care costs were reduced in ParkinsonNet clusters.
The pilot study of Brefel-Courbon et al54 assessed effec-
tiveness of spa therapy in the management of PD. In this pro-
spective, cross-over study, 31 PD patients were   randomized 
to spa therapy for three weeks and a 20-week nonspa therapy. 
The authors concluded that direct medical costs, includ-
ing radiological and laboratory tests; physician fees; drug 
therapy; and ancillary care, were slightly but significantly 
reduced in the spa period compared with the non-spa period, 
suggesting that spa therapy could be more effective and less 
expensive that conventional treatment alone. On the other 
hand, when the direct cost including direct and overhead 
costs of treatment, and consequences   including: i) patient 
outcomes (mobility, speech and   language,   disability, psycho-
logical well-being,   health-related   quality of life); ii) career 
outcomes (  psychological   well-being, health-related quality 
of life, strain); and iii) social service utilization satisfaction, 
were measured, after using a multidisciplinary rehabilita-
tion therapy (physical,   occupational, speech and language, 
specialist nurse),55 facility overheads and hospital-provided 
transport were the main costs   identified. From a patient 
perspective, the main consequences of the intervention were 
improvement of immediate outcomes for patients over four 
months; discovery of unmet social services needs; and high 
satisfaction, but no benefits for caregivers were observed.
Conclusion
In the absence of a cure, the primary goals in managing PD 
are to preserve functionality and HRQoL. There is no doubt 
that an earlier and more accurate identification of PD would 
allow us to identify individuals at high risk for   development 
of PD who could participate in trials of   medications 
designed to prevent or slow disease   progression, and at 
the end to decrease PD related expenditures. In this regard, 
studies directed toward the characterization of early signs of 
PD (eg, the Honolulu longitudinal study)56 are needed.
In PD, treatment effects and costs accumulate over time; 
hence, the choice of time horizon in cost-effectiveness 
analysis can be particularly important. Pharmaceutical 
expenditures have grown rapidly in recent decades and now 
total nearly 10% of health care costs. Although generic drug 
utilization has risen substantially at the same time, the impact 
and cost-effectiveness of generic drugs in early PD   compared 
to brand-names, remain unknown.   Decision-analytic   models 
evaluating interventions in PD have been carried out in 
  different studies. However, currently available models have 
substantial limitations. Ideally, a   comprehensive decision 
model for PD that can be applied to different treatment 
strategies should consider a large spectrum of clinically 
relevant outcomes and complications of the disease   during 
a sufficiently long time horizon, including reduction of 
  symptomatic progression; initial symptomatic improvement; 
or reduction of adverse effects, and improvement of HRQoL. 
The implementation of cost-effectiveness studies including 
the societal perspective should be considered as an outcome 
of new therapy strategies, which will be helpful to health 
care decision makers.
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